Description
by Sara Hurvitz MD (Author), Kelly McCann (Author)
Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today’s available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists.
Covers the diagnosis, treatments and targeted therapies, and management of breast cancers that are HER2-positive.
Contains sections on background and testing, advanced disease, therapeutics, and toxicity considerations.
Includes a timely section on innovative future therapies.
Product Details
- Paperback: 264 pages
- Publisher: Elsevier; 1 edition (August 30, 2018)
- Language: English
- ISBN-10: 0323581226
- ISBN-13: 978-0323581226
- Product Dimensions: 7.8 x 9.4 inches
Reviews
There are no reviews yet.